Viridian Therapeutics Q3 Lumvoa sales $24.7 million; net loss $101.2 million
Viridian Therapeutics reported third quarter 2026 results for the period ended September 30, 2026. Net product revenue from Lumvoa, its thyroid eye disease treatment in early launch, was $24.7 million, compared with no product revenue a year earlier, but the net loss widened to $101.2 million from $34.6 million as selling, general and administrative and related costs rose. Cash, cash equivalents, and marketable securities were $955.2 million at quarter end.
Key points
- Lumvoa net product revenue was $24.7 million in the quarter, with more than 100 patients on therapy at the end of Q3 2026.
- Net loss was $101.2 million, or $0.81 per share, versus $34.6 million, or $0.34 per share, in the same quarter of 2025.
- SG&A expenses rose to $57.6 million from $24.3 million, while R&D expenses fell to $70.1 million from $86.3 million.
- Cash, cash equivalents, and marketable securities were $955.2 million as of September 30, 2026; the elegrobart BLA submission is on track for Q1 2027.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.